Johnson & Johnson (NYSE:JNJ) Stock Jumps 1.4% – Here’s What Happened

Posted by Brenda Bartman on Nov 6th, 2026

Johnson & Johnson (NYSE:JNJ – Get Free Report) shares were up 1.4% on Friday. The stock traded as high as $276.41 and last traded at $276.1410. 8,805,949 shares traded hands during trading, an increase of 11% from the average session volume of 7,957,260 shares. The stock had previously closed at $272.32.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO for certain adults with recurrent or metastatic head and neck cancer whose disease progressed after specified prior treatments. The company said the supporting trial showed a 42% response rate; the approval expands the drug’s reach beyond lung cancer into a new treatment setting. Company FDA approval announcement
Positive Sentiment: J&J’s Innovative Medicine unit recorded 7.7% Q3 sales growth to $16.76 billion, with established drugs and new launches offsetting generic competition and patent-related pressure. The growth suggests the business is finding ways to counter some loss-of-exclusivity headwinds. Zacks report on Innovative Medicine sales
Neutral Sentiment: Pomerantz LLP said it is investigating investor claims involving J&J. The announcement provides no details about the claims or their merits, so its financial significance is unclear, but it may draw attention to legal risk. Pomerantz investigation announcement

Analysts Set New Price Targets

A number of research firms have weighed in on JNJ. Erste Group Bank cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Leerink Partners lowered their price target on shares of Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating on the stock in a report on Wednesday, October 14th. Wells Fargo & Company upped their price objective on Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research note on Friday, October 16th. Johnson Rice lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Wednesday, October 21st. Finally, Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $275.92.

Check Out Our Latest Report on Johnson & Johnson

Johnson & Johnson Price Performance

The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The stock has a market cap of $664.76 billion, a P/E ratio of 41.84, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22. The business’s 50-day simple moving average is $265.71 and its two-hundred day simple moving average is $248.01.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s payout ratio is currently 81.21%.

Insiders Place Their Bets

In other news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of Johnson & Johnson stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.16% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Outlook Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the second quarter worth $28,000. Matrix Trust Co grew its position in Johnson & Johnson by 56.2% during the second quarter. Matrix Trust Co now owns 150 shares of the company’s stock worth $38,000 after buying an additional 54 shares in the last quarter. Navigoe LLC grew its position in Johnson & Johnson by 60.4% during the third quarter. Navigoe LLC now owns 146 shares of the company’s stock worth $38,000 after buying an additional 55 shares in the last quarter. Montgomery Financial Services LLC purchased a new position in Johnson & Johnson during the second quarter worth about $43,000. Finally, Hanseatic Management Services Inc. bought a new position in Johnson & Johnson in the 3rd quarter worth about $52,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

(Get Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.